Brought to you by 
TMC receives option to acquire surgical sealants maker ProFibrix for $10mm up front; option exercised
26 Aug 2020
Executive Summary
The Medicines Co. (TMC; critical care products) has paid $10mm up front for an option to acquire privately held ProFibrix BV (topical surgical sealants used in hemostasis and tissue healing), which would become a wholly owned subsidiary.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
-
Surgical Equipment & Devices
- Surgical Sealants
-
Surgical Equipment & Devices
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TMC receives option to acquire surgical sealants maker ProFibrix for $10mm up front; option exercised
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice